LCTX icon

Lineage Cell Therapeutics
LCTX

Overview Fund Activity

116 hedge funds and large institutions have $138M invested in Lineage Cell Therapeutics in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 32 reducing their positions, and 12 closing their positions.

Holders
116
Holders Change
+1
Holders Change %
+0.87%
% of All Funds
1.68%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
29
Reduced
32
Closed
12
Calls
$247K
Puts
–
Net Calls
+$247K
Net Calls Change
+$233K

Top Buyers

1
BC
1
Broadwood Capital
New York
$61.7M
2
LGM
2
Logos Global Management
California
$9.25M
3
DCM
3
DAFNA Capital Management
California
$2.02M
4
Bank of America
4
Bank of America
North Carolina
$1.94M
5
RA
5
Raffles Associates
New York
$4.75M

Top Sellers

1
Morgan Stanley
1
Morgan Stanley
New York
$679K
2
Citadel Advisors
2
Citadel Advisors
Florida
$327K
3
LCM
3
Laurion Capital Management
New York
$0
4
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$4K
5
BCM
5
Bridgeway Capital Management
Texas
$1.01M
Name Market Value Shares Shares
Change 		Shares
Change %
FWM
126
Focused Wealth Management
New York
– – -8 Closed
Group One Trading
127
Group One Trading
Illinois
– – – –
CFGS
128
Concourse Financial Group Securities
Alabama
– – – –
HFS
129
Hantz Financial Services
Michigan
$0 29 – –
C
130
Covestor
United Kingdom
$0 33 +33 New
2 3 4 5
6